Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab in Chinese participants with class III or IV lupus nephritis
ISRCTN85816718Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of obinutuzumab in lupus nephritis (LN) and systemic lupus erythematosus (SLE) (4 arms), sponsored by Roche. Primary endpoint: Complete renal response at Week 76. Started Jun 2022; status: active, not recruiting.
02
Drugs
obinutuzumab
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ISRCTN85816718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN85816718.